1. INTRODUCTION
1.1. Market Overview
1.2. Market Definition
1.3. Scope of the Study
1.4. Market Segmentation
1.5. Currency
1.6. Assumptions
1.7. Base and Forecast Years Timeline
1.8. Key benefits for the stakeholders
2. RESEARCH METHODOLOGY
2.1. Research Design
2.2. Research Process
2.3. Data Validation
3. EXECUTIVE SUMMARY
3.1. Key Findings
3.2. Analyst View
4. MARKET DYNAMICS
4.1. Market Drivers
4.2. Market Restraints
4.3. Porter’s Five Forces Analysis
4.3.1. Bargaining Power of Supplier
4.3.2. Bargaining Power of Buyers
4.3.3. Threat of New Entrants
4.3.4. Threat of Substitutes
4.3.5. Competitive Rivalry in the Industry
4.4. Industry Value Chain Analysis
5. EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET BY DRUGS
5.1. Introduction
5.2. Histone Deacetylase (HDAC) Inhibitors
5.3. DNA Methyltransferase (DNMT) Inhibitors
5.4. Others
6. EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET BY TECHNOLOGY
6.1. Introduction
6.2. Reagents
6.3. Kits
6.3.1. Chip Sequencing Kit
6.3.2. Whole Genomic Amplification Kit
6.3.3. Bisulfite Conversion Kit
6.3.4. RNA Sequencing Kit
6.4. Instruments
6.5. Services
6.6. Others
7. EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET BY APPLICATION
7.1. Introduction
7.2. Oncology
7.3. Non-oncology
7.3.1. Inflammatory Diseases
7.3.2. Metabolic Diseases
7.3.3. Infectious Diseases
7.3.4. Cardiovascular Diseases
7.3.5. Others
8. EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET BY GEOGRAPHY
8.1. Global Overview
8.2. North America
8.2.1. United States
8.2.2. Canada
8.2.3. Mexico
8.3. South America
8.3.1. Brazil
8.3.2. Argentina
8.3.3. Rest of South America
8.4. Europe
8.4.1. United Kingdom
8.4.2. Germany
8.4.3. France
8.4.4. Italy
8.4.5. Spain
8.4.6. Rest of Europe
8.5. Middle East and Africa
8.5.1. Saudi Arabia
8.5.2. United Arab Emirates
8.5.3. Rest of the Middle East and Africa
8.6. Asia-Pacific
8.6.1. China
8.6.2. India
8.6.3. Japan
8.6.4. South Korea
8.6.5. Taiwan
8.6.6. Thailand
8.6.7. Indonesia
8.6.8. Rest of Asia-Pacific
9. COMPETITIVE ENVIRONMENT AND ANALYSIS
9.1. Major Players and Strategy Analysis
9.2. Emerging Players and Market Lucrativeness
9.3. Mergers, Acquisitions, Agreements, and Collaborations
9.4. Competitive Dashboard
10. COMPANY PROFILES
10.1. Roche Diagnostics
10.2. Thermo Fisher Scientific, Inc.
10.3. Element Biosciences, Inc.
10.4. Dovetail Genomics LLC.
10.5. Abcam plc.
10.6. Eisai Co., Ltd.
10.7. Novartis AG
10.8. Cantata Bio
10.9. Illumina, Inc.
10.10. Promega Corporation
10.11. Merck KGaA